<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37595172</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-4221</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>International journal of pharmaceutical compounding</Title><ISOAbbreviation>Int J Pharm Compd</ISOAbbreviation></Journal><ArticleTitle>Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>293</EndPage><MedlinePgn>284-293</MedlinePgn></Pagination><Abstract><AbstractText>People infected by severe acute respiratory&#xa0;coronavirus 2 (SARS-CoV-2) risk&#xa0;the development of not only acute coronavirus-&#xa0;disease-2019 (COVID-19) - the&#xa0;signs and symptoms of which range from&#xa0;none to severe illness that requires intensive&#xa0;treatment - but also long COVID&#xa0;(i.e., chronic COVID), a cyclical, progressive,&#xa0;multiphasic illness characterized by&#xa0;myriad debilitating conditions that persist&#xa0;long term. In some patients, those&#xa0;sequelae result in psychiatric disorders&#xa0;that can lead to suicide or other forms&#xa0;of self-harm, incidences of which have&#xa0;increased exponentially since before the&#xa0;COVID pandemic. It has been suggested&#xa0;that long COVID develops in an estimated&#xa0;10% to 35% of people diagnosed as having&#xa0;COVID-19. Because the success of therapy&#xa0;for either form of COVID can be complicated&#xa0;by each patient's pharmacogenomic&#xa0;profile, personal treatment preferences,&#xa0;medical needs, and/or dosing requirements,&#xa0;we have found that in some people&#xa0;so afflicted, manufactured medications&#xa0;are ineffective or intolerable, and that for&#xa0;those individuals, a customized compound&#xa0;often provides relief and promotes recovery.&#xa0;The primary focus of this article is long&#xa0;COVID. The pathogenesis of that disease&#xa0;is reviewed, therapies for the signs and&#xa0;symptoms it engenders are examined, and&#xa0;2 compounded formulations effective in&#xa0;treating both acute and chronic COVID-19&#xa0;are presented.</AbstractText><CopyrightInformation>Copyright&#xa9; by International Journal of Pharmaceutical Compounding, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riepl</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Retired Compounding Pharmacist, Bismarck, North Dakota. flintlock@bis.midco.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dakota PrecisionRx Labs, Bismarck, North Dakota. joe@precisionrxlabs.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Pharm Compd</MedlineTA><NlmUniqueID>9706294</NlmUniqueID><ISSNLinking>1092-4221</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37595172</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>